What CGRP mAbs Are and Why They Matter for Migraine
CGRP monoclonal antibodies, commonly called CGRP mAbs, are a class of preventive medications designed specifically for migraine. Unlike older preventives that were borrowed from other disease areas, CGRP mAbs were built around a single, well-understood pathway: the calcitonin gene-related peptide. By binding to CGRP or its receptor, these drugs reduce the inflammatory signaling that helps trigger and sustain migraine attacks. The result is a treatment that works on the biology of migraine without the broad systemic side effects of drugs like topiramate or propranolol.
- What CGRP mAbs Are and Why They Matter for Migraine
- How the CGRP Pathway Drives Migraine
- Approved CGRP mAb Drugs and Dosing Schedules
- Who Qualifies for CGRP mAb Treatment
- What to Expect: Efficacy and Timeline
- Side Effects and Safety Considerations
- Access, Cost, and Practical Factors
- Looking Ahead: The Evolving Role of CGRP mAbs
More from this site
Keep reading the latest coverage
For people who have tried and failed multiple preventives, or who cannot tolerate them, CGRP mAbs represent a targeted option with a distinct safety profile. They are administered by injection, typically once a month or once every three months, which makes them easier to stick with than daily pills for many patients.
How the CGRP Pathway Drives Migraine
CGRP is a neuropeptide released around the brain during migraine. It dilates blood vessels, promotes inflammation, and sensitizes pain fibers in the meninges. That chain of events contributes to the throbbing pain, nausea, and sensitivity to light and sound that define an attack. CGRP mAbs interrupt this process before it amplifies.
The four approved CGRP mAbs work in two ways. Erenumab blocks the CGRP receptor, so CGRP cannot attach and send its signal. The other three drugs — galcanezumab, fremanezumab, and eptinezumab — bind directly to the CGRP molecule itself, neutralizing it before it reaches the receptor. Because the target is the same pathway, patients who do not respond to one may still respond to another, though individual results vary.
Approved CGRP mAb Drugs and Dosing Schedules
Each CGRP mAb has a specific dosing schedule, which matters for adherence and lifestyle fit.
| Drug | Mechanism | Dosing | Route |
|---|---|---|---|
| Erenumab | CGRP receptor antagonist | 70 mg or 140 mg monthly | Subcutaneous injection |
| Galcanezumab | Anti-CGRP antibody | 240 mg loading, then 120 mg monthly | Subcutaneous injection |
| Fremanezumab | Anti-CGRP antibody | 225 mg monthly or 675 mg quarterly | Subcutaneous injection |
| Eptinezumab | Anti-CGRP antibody | 100 mg or 300 mg every 3 months | Intravenous infusion |
Who Qualifies for CGRP mAb Treatment
CGRP mAbs are approved for episodic and chronic migraine in adults. They are typically considered when traditional preventives have been ineffective, poorly tolerated, or contraindicated. Because these drugs are newer and often more expensive, insurers usually require step therapy, meaning patients must try and fail older oral preventives first. In practice, some clinicians prescribe them earlier for patients with specific risk factors or contraindications to conventional options.
Candidates should discuss their full migraine history, including frequency, disability, and prior treatments, with a headache specialist or neurologist. The decision to start a CGRP mAb depends on individual response patterns, comorbidities, and access.
What to Expect: Efficacy and Timeline
Clinical trials show that CGRP mAbs reduce monthly migraine days by an average of several days compared to placebo, with some patients achieving a 50% or greater reduction in attack frequency. Response is not immediate; most clinicians assess benefit after two to three months of consistent use. A subset of patients experience a meaningful drop in attack severity and duration, while others see more modest improvement.
If a first CGRP mAb does not provide adequate relief, switching to another agent in the class can be worthwhile. The drugs share a target but differ in structure, binding affinity, and dosing, so one may succeed where another did not.
Side Effects and Safety Considerations
CGRP mAbs are generally well tolerated. The most common side effects include injection-site reactions such as redness, swelling, or discomfort. Constipation is reported with erenumab, likely because CGRP plays a role in gut motility. Serious adverse events are rare, but patients should inform their prescriber of any new or worsening symptoms.
Long-term safety data continue to accumulate. Because CGRP also has roles in cardiovascular regulation, patients with uncontrolled hypertension or recent cardiovascular events should be evaluated carefully before starting treatment. Pregnancy and breastfeeding require individualized risk-benefit discussions.
Access, Cost, and Practical Factors
CGRP mAbs are administered in a clinical setting or at home, depending on the drug. Eptinezumab requires an intravenous infusion, while the others are self-injectable with pre-filled syringes or autoinjectors. Manufacturer copay cards and patient assistance programs can reduce out-of-pocket costs, though coverage varies by plan and region.
Real-world persistence rates are influenced by injection burden, cost, and perceived benefit. Patients who are proactive about scheduling doses, tracking migraine days, and communicating with their care team tend to get more value from treatment over time.
Looking Ahead: The Evolving Role of CGRP mAbs
The CGRP mAb class has reshaped migraine prevention by proving that targeting a single pathway can deliver meaningful benefit for a large number of patients. Ongoing research explores biomarkers that predict response, combination strategies, and new formulations that could broaden access. For now, CGRP mAbs remain a cornerstone option for anyone seeking a mechanism-based, injectable preventive with a favorable side effect profile.